Chai-2 achieves 16–20% hit rates in de novo antibody design against 52 clinical targets

Chai Discovery/Chai-2

Chai Discovery published results showing Chai-2 achieves 16–20% hit rates when designing antibodies from scratch against 52 diverse clinical targets. This represents roughly 100x improvement over prior computational methods. Experimental validation confirmed that designed antibodies exhibit nanomolar-range binding affinities, target specificity, and drug-like properties suitable for therapeutic development.